Glokomun Tıbbi Tedavisinde Yenilikler

Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901-1911. doi:10.1001/jama.2014.3192

Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090. doi:10.1016/j.ophtha.2014.05.013

Harasymowycz P, Birt C, Gooi P, et al. Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. J Ophthalmol. 2016;2016:6509809. doi:10.1155/2016/6509809

Chang EE, Goldberg JL. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology. 2012;119(5):979-986. doi:10.1016/j.ophtha.2011.11.003

MacIver S, MacDonald D, Prokopich CL. Screening, diagnosis, and management of open angle glaucoma: an evidence-based guideline for Canadian optometrists. Can J Optometry 2017;79.

Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417-428. doi:10.1016/j.jval.2011.04.002

Kopczynski CC, Epstein DL. Emerging trabecular outflow drugs. J Ocul Pharmacol Ther. 2014;30(2-3):85-87. doi:10.1089/jop.2013.0197

Thieme H, Nuskovski M, Nass JU, et al. Mediation of calcium-independent contraction in trabecular meshwork through protein kinase C and rho-A. Invest Ophthalmol Vis Sci. 2000;41(13):4240-4246.

Rao PV, Deng PF, Kumar J, et al. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632 [published correction appears in Invest Ophthalmol Vis Sci 2001 Jul;42(8):1690]. Invest Ophthalmol Vis Sci. 2001;42(5):1029-1037.

Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94(1):e26-e34. doi:10.1111/aos.12829

Tanihara H, Inoue T, Yamamoto T, et al. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials. JAMA Ophthalmol. 2015;133(7):755-761. doi:10.1001/jamaophthalmol.2015.0525

Wang RF, Williamson JE, Kopczynski C, et al. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24(1):51-54. doi:10.1097/IJG.0b013e3182952213

Kiel JW, Kopczynski CC. Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits. J Ocul Pharmacol Ther. 2015;31(3):146-151. doi:10.1089/jop.2014.0146

Bacharach J, Dubiner HB, Levy B, et al; AR-13324-CS202 Study Group. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122(2):302-307. doi:10.1016/j.ophtha.2014.08.022

Serle JB, Katz LJ, McLaurin E, et al. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116-127. doi:10.1016/j.ajo.2017.11.019

Asrani S, Bacharach J, Holland E, et al. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2. Adv Ther. 2020;37(4):1620-1631. doi:10.1007/s12325-020-01277-2

Aerie Pharmaceuticals Inc. Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02%/0.005%) ophthalmic solution compared to ganfort® ophthalmic solution in open angle glaucoma or ocular hypertension. 15 September 2017 ed. ClinicalTrials.gov: NIH U.S. National Library of Medicine; 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03284853.

Pakravan M, Beni AN, Ghahari E, et al. The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma. Am J Ther. 2017;24(6):e676-e680. doi:10.1097/MJT.0000000000000362.

Wada Y, Higashide T, Nagata A, et al. Effects of ripasudil, a rho kinase inhibitor, on blood flow in the optic nerve head of normal rats. Graefes Arch Clin Exp Ophthalmol. 2019;257(2):303-311. doi:10.1007/s00417-018-4191-6

Honjo M, Tanihara H, Kameda T, et al. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007;48(12):5549-5557. doi:10.1167/iovs.07-0878

Hoy SM. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension [published correction appears in Drugs. Drugs. 2018;78(7):773-780. doi:10.1007/s40265-018-0914-6

Liu JHK, Slight JR, Vittitow JL, et al. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours. Am J Ophthalmol. 2016;169:249-257. doi:10.1016/j.ajo.2016.04.019

Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738-745. doi:10.1136/bjophthalmol-2014-305908

Kawase K, Vittitow JL, Weinreb RN, et al; JUPITER Study Group. Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study. Adv Ther. 2016;33(9):1612-1627. doi:10.1007/s12325-016-0385-7

Harasymowycz P, Royer C, Cui AX, et al. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. Br J Ophthalmol. 2022;106(5):640-647. doi:10.1136/bjophthalmol-2020-317262

Medeiros FA, Walters TR, Kolko M, et al. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627-1641. doi:10.1016/j.ophtha.2020.06.018

Chen MY, Sall KN, Tepedino M, et al. Patient reported outcomes of bimatoprost ocular ring in an open-label extension study in patients with openangle glaucoma or ocular hypertension, Invest. Ophthalmol. Vis Sci. 2018;59:1231.

Wu T, Sheybani A. Review of glaucoma drug delivery systems. Ophthalmol Manag. 2020;24:27–28.

Glaukos Corporation, Glaukos’ iDoseVR TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study, Press Releases. 2021

Navratil T, Garcia A, Verhoeven RS, et al. Advancing ENV515 (travoprost) intracameral implant into clinical development: nonclinical evaluation of ENV515 in support of first-time-in-human phase 2a clinical study. Invest Ophthalmol Vis Sci. 2015;56:5706.

Perera SA, Ting DS, Nongpiur ME, et al. Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population. Clin Ophthalmol. 2016;10:757-764. doi:10.2147/OPTH.S102181

Goldberg DF, Williams R. Phase A. 2 study evaluating safety and efficacy of the Latanoprost Punctal Plug Delivery System (L-PPDS) in subjects with Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG). Invest Ophthalmol Vis Sci. 2012;53:5095.

Peng CC, Ben-Shlomo A, Mackay EO, et al. Drug delivery by contact lens in spontaneously glaucomatous dogs. Curr Eye Res. 2012;37(3):204-211. doi:10.3109/02713683.2011.630154

Ciolino JB, Ross AE, Tulsan R, et al. Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys. Ophthalmology. 2016;123(10):2085-2092. doi:10.1016/j.ophtha.2016.06.038

Jung HJ, Abou-Jaoude M, Carbia BE, et al. Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses. J Control Release. 2013;165(1):82-89. doi:10.1016/j.jconrel.2012.10.010

Mehta P, Al-Kinani AA, Arshad MS, et al. Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses. J Pharm Sci. 2019;108(4):1540-1551. doi:10.1016/j.xphs.2018.11.036

Xu J, Ge Y, Bu R, et al. Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma. J Control Release. 2019;305:18-28. doi:10.1016/j.jconrel.2019.05.025

Kim HJ, Zhang K, Moore L, et al. Diamond nanogel-embedded contact lenses mediate lysozyme-dependent therapeutic release. ACS Nano. 2014;8(3):2998-3005. doi:10.1021/nn5002968

Mehta P, Al-Kinani AA, Arshad MS, et al. Development and characterisation of electrospun timolol maleate-loaded polymeric contact lens coatings containing various permeation enhancers. Int J Pharm. 2017;532(1):408-420. doi:10.1016/j.ijpharm.2017.09.029

Ding X, Ben-Shlomo G, Que L. Soft Contact Lens with Embedded Microtubes for Sustained and Self-Adaptive Drug Delivery for Glaucoma Treatment. ACS Appl Mater Interfaces. 2020;12(41):45789-45795. doi:10.1021/acsami.0c12667

Jung HJ, Chauhan A. Temperature sensitive contact lenses for triggered ophthalmic drug delivery. Biomaterials. 2012;33(7):2289-2300. doi:10.1016/j.biomaterials.2011.10.076

Tighsazzadeh M, Mitchell JC, Boateng JS. Development and evaluation of performance characteristics of timolol-loaded composite ocular films as potential delivery platforms for treatment of glaucoma. Int J Pharm. 2019;566:111-125. doi:10.1016/j.ijpharm.2019.05.059.

Occhiutto ML, Maranhão RC, Costa VP, et al. Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review. Adv Ther. 2020;37(1):155-199. doi:10.1007/s12325-019-01163-6

Aref AA. Sustained drug delivery for glaucoma: current data and future trends. Curr Opin Ophthalmol. 2017;28(2):169-174. doi:10.1097/ICU.0000000000000334

Passani A, Posarelli C, Sframeli AT, et al. Cannabinoids in Glaucoma Patients: The Never-Ending Story. J Clin Med. 2020;9(12):3978. doi:10.3390/jcm9123978.

Plange N, Arend KO, Kaup M, et al. Dronabinol and retinal hemodynamics in humans. Am J Ophthalmol. 2007;143(1):173-174. doi:10.1016/j.ajo.2006.07.053

Hommer N, Kallab M, Szegedi S, et al. The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial. Clin Pharmacol Ther. 2020;108(1):155-161. doi:10.1002/cpt.1797

Tomida I, Azuara-Blanco A, House H, et al. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006;15(5):349-353. doi:10.1097/01.ijg.0000212260.04488.60

Merritt JC, Crawford WJ, Alexander PC, et al. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980;87(3):222-228. doi:10.1016/s0161-6420(80)35258-5

Jay WM, Green K. Multiple-drop study of topically applied 1% delta 9-tetrahydrocannabinol in human eyes. Arch Ophthalmol. 1983;101(4):591-593. doi:10.1001/archopht.1983.01040010591012

Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011;5:667-677. doi:10.2147/OPTH.S15971

Myers JS, Sall KN, DuBiner H, et al. A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma. J Ocul Pharmacol Ther. 2016;32(8):555-562. doi:10.1089/jop.2015.0148

Aihara M, Lu F, Kawata H, et al. Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study. Am J Ophthalmol. 2020;220:53-63. doi:10.1016/j.ajo.2020.06.003

Miller Ellis E, Berlin MS, Ward CL, et al. Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study. Br J Ophthalmol. 2017;101(6):796-800. doi:10.1136/bjophthalmol-2016-309023

Martínez T, González MV, Roehl I, et al. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther. 2014;22(1):81-91. doi:10.1038/mt.2013.216

Gupta A, Kafetzis KN, Tagalakis AD, et al. RNA therapeutics in ophthalmology - translation to clinical trials. Exp Eye Res. 2021;205:108482. doi:10.1016/j.exer.2021.108482

Schwartz M, Yoles E. Neuroprotection: a new treatment modality for glaucoma?. Curr Opin Ophthalmol. 2000;11(2):107-111. doi:10.1097/00055735-200004000-00007

Vasudevan SK, Gupta V, Crowston JG. Neuroprotection in glaucoma. Indian J Ophthalmol. 2011;59 Suppl(Suppl1):S102-S113. doi:10.4103/0301-4738.73700

Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res. 1997;37(24):3483-3493. doi:10.1016/S0042-6989(97)00047-3

Weinreb RN, Liebmann JM, Cioffi GA, et al. Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies. Ophthalmology. 2018;125(12):1874-1885. doi:10.1016/j.ophtha.2018.06.017

Chrysostomou V, Rezania F, Trounce IA, et al. Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol. 2013;13(1):12-15. doi:10.1016/j.coph.2012.09.008

Krupin T, Liebmann JM, Greenfield DS, et al; Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;151(4):671-681. doi:10.1016/j.ajo.2010.09.026

Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2017;1(1):CD006539. doi:10.1002/14651858.CD006539.pub4

Zhai J, Bo Y, Lu Y, et al. Effects of Coenzyme Q10 on Markers of Inflammation: A Systematic Review and Meta-Analysis. PLoS One. 2017;12(1):e0170172. doi:10.1371/journal.pone.0170172

Rocco ML, Soligo M, Manni L, et al. Nerve Growth Factor: Early Studies and Recent Clinical Trials. Curr Neuropharmacol. 2018;16(10):1455-1465. doi:10.2174/1570159X16666180412092859

Kimura A, Namekata K, Guo X, et al. Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal Degeneration. Int J Mol Sci. 2016;17(9):1584. doi:10.3390/ijms17091584

Stone EM, Fingert JH, Alward WL, et al. Identification of a gene that causes primary open angle glaucoma. Science. 1997;275(5300):668-670. doi:10.1126/science.275.5300.668

Rezaie T, Child A, Hitchings R, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science. 2002;295(5557):1077-1079. doi:10.1126/science.1066901

Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum Mol Genet. 1997;6(4):641-647. doi:10.1093/hmg/6.4.641

Thorleifsson G, Magnusson KP, Sulem P, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science. 2007;317(5843):1397-1400. doi:10.1126/science.1146554

Demetriades AM. Gene therapy for glaucoma. Curr Opin Ophthalmol. 2011;22(2):73-77. doi:10.1097/ICU.0b013e32834371d2

Gerometta R, Spiga MG, Borrás T, et al. Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus. Invest Ophthalmol Vis Sci. 2010;51(6):3042-3048. doi:10.1167/iovs.09-4920

Harvey AR, Kamphuis W, Eggers R, et al. Intravitreal injection of adeno-associated viral vectors results in the transduction of different types of retinal neurons in neonatal and adult rats: a comparison with lentiviral vectors. Mol Cell Neurosci. 2002;21(1):141-157. doi:10.1006/mcne.2002.1168

Wu J, Bell OH, Copland DA, et al. Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9. Mol Ther. 2020;28(3):820-829. doi:10.1016/j.ymthe.2019.12.012

Barraza RA, McLaren JW, Poeschla EM. Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure. Mol Ther. 2010;18(3):491-501. doi:10.1038/mt.2009.278

Comes N, Borrás T. Individual molecular response to elevated intraocular pressure in perfused postmortem human eyes. Physiol Genomics. 2009;38(2):205-225. doi:10.1152/physiolgenomics.90261.2008

Isenmann S, Klöcker N, Gravel C, et al. Short communication: protection of axotomized retinal ganglion cells by adenovirally delivered BDNF in vivo. Eur J Neurosci. 1998;10(8):2751-2756. doi:10.1046/j.1460-9568.1998.00325.x

Pease ME, Zack DJ, Berlinicke C, et al. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci. 2009;50(5):2194-2200. doi:10.1167/iovs.08-3013

Munemasa Y, Ahn JH, Kwong JM, et al. Redox proteins thioredoxin 1 and thioredoxin 2 support retinal ganglion cell survival in experimental glaucoma. Gene Ther. 2009;16(1):17-25. doi:10.1038/gt.2008.126

Harrell CR, Fellabaum C, Arsenijevic A, et al. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of Glaucoma. Stem Cells Int. 2019;2019:7869130. doi:10.1155/2019/7869130

Sun H, Zhu Q, Guo P, et al. Trabecular meshwork cells are a valuable resource for cellular therapy of glaucoma. J Cell Mol Med. 2019;23(3):1678-1686. doi:10.1111/jcmm.14158

Zhu W, Jain A, Gramlich OW, et al. Restoration of Aqueous Humor Outflow Following Transplantation of iPSC-Derived Trabecular Meshwork Cells in a Transgenic Mouse Model of Glaucoma. Invest Ophthalmol Vis Sci. 2017;58(4):2054-2062. doi:10.1167/iovs.16-20672

Inman DM, Lambert WS, Calkins DJ, et al. α-Lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction. PLoS One. 2013;8(6):e65389. doi:10.1371/journal.pone.0065389

Mutolo MG, Albanese G, Rusciano D, et al. Oral Administration of Forskolin, Homotaurine, Carnosine, and Folic Acid in Patients with Primary Open Angle Glaucoma: Changes in Intraocular Pressure, Pattern Electroretinogram Amplitude, and Foveal Sensitivity. J Ocul Pharmacol Ther. 2016;32(3):178-183. doi:10.1089/jop.2015.0121

Labkovich M, Jacobs EB, Bhargava S, et al. Ginkgo Biloba Extract in Ophthalmic and Systemic Disease, With a Focus on Normal-Tension Glaucoma. Asia Pac J Ophthalmol (Phila). 2020;9(3):215-225. doi:10.1097/APO.0000000000000279

Roberti G, Tanga L, Michelessi M, et al. Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives. Int J Mol Sci. 2015;16(12):28401-28417. doi:10.3390/ijms161226099

Virno M, Pecori-Giraldi J, Liguori A, et al. The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmol Scand Suppl. 2000;(232):56-57. doi:10.1111/j.1600-0420.2000.tb01107.x

Ottobelli L, Manni GL, Centofanti M, et al. Citicoline oral solution in glaucoma: is there a role in slowing disease progression?. Ophthalmologica. 2013;229(4):219-226. doi:10.1159/000350496

Parisi V. Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5'-diphosphocholine (citicoline): a study of 8 years of follow-up. Doc Ophthalmol. 2005;110(1):91-102. doi:10.1007/s10633-005-7348-7

Rejdak R, Toczołowski J, Kurkowski J, et al. Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit. 2003;9(3):PI24-PI28.

Rossetti L, Iester M, Tranchina L, et al. Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial. J Glaucoma. 2020;29(7):513-520. doi:10.1097/IJG.0000000000001565